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Background: Coffee includes some potentially bioactive components that can interfere with platelets,
which can influence coagulation, despite generating controversy. The aim of this systematic review is to
verify whether coffee or its components can influence platelet regulators and/or aggregation.
Materials and Methods: The research was conducted on July 29, 2021, in PubMed, Scopus, and Web of Sci-
ence, using the following mesh-terms: (caffeine)) OR (coffee)) AND (platelets). Eligibility criteria were: stud-
ies carried out in humans, referring to the effects of coffee consumption, or one of its components, on platelets
or their regulators. We exclude in vitro or animal studies, reviews, editorials, and non-English written studies.
From a total of 836 publications, 17 articles were included from which we extracted the relationship between
coffee consumption and changes in blood platelets and performed a subjective assessment of bias.
Results: Ten articles refer to the non-interference of coffee or its components with platelets, nine affirm
results that support the increase in platelet aggregation, and eight articles observe the decrease in platelet
aggregation when coffee is consumed. Some articles presented the lack of data regarding the sample col-
lection location, age group, or classification as to the type of study, which is limiting.
Conclusions: The heterogeneity of results makes it difficult to correctly interpret the possible interaction of
coffee or its components with platelets or their regulators. For better interpretation, further studies on this
topic should be carried out considering the individualization of coffee components, different platelet reg-
ulators, and the size of the sample used.
Keywords: caffeine, thromboxane B2, adenosine receptors A2A, platelet aggregation
Introduction
Coffee is a beverage widely consumed worldwide,and it is produced from roasted coffee beans that
are extracted and processed by a dry or wet technique.1
This drink includes some potentially bioactive compo-
nents, such as caffeine, diterpenes, and polyphenols,
such as chlorogenic acid (CGA), quinides, and lactones.2
Caffeine (1,3,7-trimethylxanthine) belongs to the group
of methylxanthines, and its absorption occurs in the gastro-
intestinal tract into the bloodstream.3,4 Taking into account
its lipophilic properties, it is evenly distributed in all body
fluids and all organs.4 Caffeine metabolism occurs mainly
in the liver,3,5 being affected by exogenous and endoge-
nous factors.5 Excretion occurs predominantly by the
renal pathway.4 The most common polyphenols in coffee
are quinidines, lactones, and CGA,1 which exhibit many
biological properties, including antibacterial, antioxidant,
and anti-inflammatory activity, particularly hypoglycemic,
hypolipidemic effects6–8 and antiplatelet activity, which
may result in cardiovascular protection.9,10 The phenolic
portion of CGA is named caffeic acid and is available
for absorption, almost entirely, in the small intestine,
after hydrolysis.11,12 Most diterpenes are esterified with
different types of fatty acids,13 with the main pentacyclic
diterpenes being found in coffee, cafestol, and Caveol,2,14
which have antioxidant and potentially hyperlipemiant ef-
fects, especially on cholesterol plasmatic levels. Cafestol
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has 80% of the potential for elevating low-density lipopro-
tein (LDL) and 20% of the potential for elevating very
LDL.15
Due to its constitution, coffee contributes toward health
benefits, through stimulation of the central nervous system,
cardiovascular muscle, respiratory system, as well as di-
uretic and fatigue reduction.16–18 It improves energy levels;
improves various aspects of brain function such as mem-
ory, mood, alertness, energy levels, reaction times, and
general cognitive function;19,20 may reduce the risk of mor-
tality and chronic diseases such as cancer and stroke;21,22
and reduces the moderate consumption of cardiovascular
risk.23 The health risks from drinking coffee include adre-
nal fatigue, irregular heartbeat, and hallucinations; coffee
accelerates bone loss, tremors24,25 and in high doses it
seems to increase the risk of miscarriage during pregnan-
cy.26 Overdrinking 28 cups of coffee or more per week in-
creased the probability of dying prematurely by 21%,27
and studies reported that the drinking of boiled coffee is as-
sociated with an elevated risk for cardiovascular dis-
ease,27,28 despite inconsistencies.29
Platelets or thrombocytes are derived from cellular
fragments of bone marrow precursor megakaryocytes30
and are non-nucleated blood components recognized as
the primary cells that regulate hemostasis and thrombo-
sis, contributing to blood clotting, among other immuno-
logical and inflammatory functions31,32 (Fig. 1). Under
normal physiological conditions, they circulate in close
contact with the endothelial lining of the blood vessel
wall33; however, as a biological response to changes in
the organism (injuries, inflammation/sepsis, among oth-
ers),34 platelets respond to changes in the endothelial
cell wall fixing at the lesion site, and originating aggre-
gates of platelets or thrombi33 (Fig. 2). Depending on
the type of change, to which platelets respond, this plate-
let adhesion will start the process of primary hemostasis,
followed by platelet activation, which is initiated by var-
ious stimuli, such as adenosine diphosphate (ADP).35
Then there is the secretion of aggregating substances
and, finally, platelet aggregation.35 Prostanoids are eico-
soids, a group to which prostacyclins, prostaglandins,
and thromboxanes belong. Among these, prostacyclins,36
prostaglandin I2 (PGI2),37 and cyclic 3’5’-adenosine
monophosphate (cyclic AMP or cAMP) are regulators
that have antiplatelet action. On the other hand, throm-
boxane A2 (TXA2) and thromboxane B2 (TXB2) have
aggregating action,36 as well as the inhibitor of plasmin-
ogen activator type 1 (PAI-1) that can promote the per-
manence of the fibrin clot inhibiting fibrinolysis.38
Methylxanthines, such as caffeine, are non-selective
blockers of the adenosine receptor33 and act especially
on the A2A receptor, specifically expressed in plate-
lets.33,39 Regarding platelet aggregation, in vitro studies
indicate caffeine as a phosphodiesterase blocker, which
blocks the conversion of cAMP into 5-AMP, increasing
cAMP, with consequent inhibition of platelet aggrega-
tion.33,39,40 Some studies have shown that CGA inhibited
ADP-induced platelet secretion and aggregation, colla-
gen, arachidonic acid, and thrombin receptor activating
peptide and also showed a decrease in platelet adhe-
sion/aggregation and platelet–leukocyte interaction.41
However, there are studies whose results have shown
that neither coffee42 nor caffeine35 affected platelet
aggregation.
This systematic review article aims at understanding
the effect that coffee or its components have on platelets
or their regulators, to contribute with scientific informa-
tion relevant to the understanding of interactions at the
health level.
Materials and Methods
This study is a systematic review of the literature to as-
certain the effects of coffee consumption on platelets and
FIG. 1. Platelet formation.























































their regulators and it was prepared according to the
PRISMA recommendations,43 whose checklist is pre-
sented in the Supplementary Data (Supplementary File
S1).44 These guidelines consist of a flow chart (criteria
for identification, screening, eligibility, and inclusion of
articles that fall under a review) and a checklist of 27
items.45 There is no review protocol registered.
Research question
A research question was defined according to PICO
criteria46: What is the effect of coffee consumption on
platelets or on their regulators?
P (Population): Humans.
I (Intervention/Exhibition): Consumption of coffee or
its components.
C (Comparation): No/Low consumption of coffee
and/or its components (caffeine, diterpenes, CGA).
O (Evaluation/Outcomes): Blood platelets and/or their
regulators (TxB2, phosphodiesterases (PDE), adenosine
receptors, PGI2 and PAI-1).
Eligibility criteria
For this review, original articles were considered
whose studies were carried out in humans, referring to
the effects of coffee consumption, or one of its compo-
nents, on platelets or their regulators.
The exclusion criteria considered were in vitro studies
or animal models, as well as review articles, editorials or
those written in languages other than English.
Research strategy and descriptors
The electronic searches were performed independently
on July 29, 2021, in PubMed, Scopus, and Web of Sci-
ence, using the mesh-terms: (caffeine)) OR (coffee))
AND (platelets). Detailed information is presented in
Supplementary Data (Supplementary File S2).
Screening and selection of studies
This search resulted in a total of 836 publications
found. After eliminating 306 duplicates, a total of 530
publications were screened. A total of 143 studies were
FIG. 2. Platelet me-
tabolism.























































considered eligible, and 17 were included in this review.
The flowchart47 demonstrates the detailed selection pro-
cess (Fig. 3).
Study tabulation
To summarize the studies included in this review,
Table 1 highlights the most important characteristics.
Data depicted: author, year and reference, sample collec-
tion location, sample characteristics (size, gender and
age, body mass index), study design (duration, coffee
or its components, platelets or their regulators), conclu-
sions (relationship between coffee consumption and
blood platelets), and classification of possible bias.
Results
We included 17 experimental studies in this systematic
review article, classified into randomized controlled tri-
als,48–50 self-controlled trials,39,40,51–56 and crossover
trials,57–60 and two studies are apparently parallel tri-
als.42,61 Only three studies referred to the sample collec-
tion site, which was at the University of Kaiserslautern in
Germany,60 University of California at Davis,61 and with
members of a Department of Nutrition.50 The sample
size of the studies is variable, with 3 studies covering 8
individuals,51,55,59 1 study covering 9,39 2 studies using
10 individuals,57,60 another 2 involving 12 people,42,52
2 articles mentioning 13 participants,40,54 only 1 using
a sample of 14 people,56 one betting on a sample of 20
individuals,50 another 2 using 2649 and 27 people,53 re-
spectively, one study collecting a sample of 31 people,61
and 2 studies encompassing a larger sample size with
4548 and 84 individuals,58 respectively (Table 1).
To perform a qualitative analysis, through a bias anal-
ysis,62 seven articles40,42,49–51,54,59 may present a non-
differential bad classification bias, since they do not
detect a relationship between the studied variables.
Two articles may present bias in social desirability57,59
insofar as the recruited individuals may claim moderate
consumption of coffee, as they consider it the most cor-
rect, and do not correspond to reality. Three articles pres-
ent a loss of follow-up bias, either by correspondence to
FIG. 3. Flowchart of screening and
selection of the studies.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exclusion criteria,61 occurrence of adverse effects,40 or
for personal reasons.60 One of the articles has an error
in that there is no indication of the age range of its sam-
ple.49 In the remaining articles, no bias was identified,
but confounding variables may exist, in relation to gen-
der (female and male) and/or age (with significant differ-
ences in age groups).
Four articles mention coffee and prostanoids,42,51,57,61
two articles refer to coffee with PDE and cAMP,58,60 one
of which also refers to the relationship between CGA and
the PDE and cAMP,60 only one of the articles relates cof-
fee to the adenosine receptors,58 two refer to caffeine
with the same,39,55 five articles focus on the relationship
between coffee and platelets,49,50,53,57,59 seven focus on
caffeine with platelets,40,48,50,52,54,56,57 only one of the
articles speaks of the relationship between caffeine and
PAI-1,56 and two report on caffeine with 5’-N-
ethylcarboxamidoadenosine (NECA).39,55
Although the articles did not report a gender differ-
ence in platelets, regarding coffee consumption, it is
noteworthy that CYP1A2 is an isoenzyme involved in
the metabolism of several drugs, including the
N-hydroxylation of caffeine.63 There is less activity
of cytochrome P450 Family 1 Subfamily A Member 2
(CYPIA2), in women compared with men, and the
elimination of its substrates is significantly higher in
men than in women.63
Coffee and prostanoids
From the studies observed, it was found that two42,51
concluded that there was no effect of coffee at the
TXB2 level, that is, after a three-week treatment period
with coffee (8 cups of coffee per day42 or 50 mL of hot
decaffeinated coffee51) there were no changes in this
prostanoid. However, another study57 reveals that after
an acute consumption of 200 mL of American coffee,
there was an inhibition of the formation of TXB2.57
Regarding PGI2, only one study61 focused on it, veri-
fying that consuming coffee acutely there was no in-
crease in this prostanoid.61
Coffee, PDE, and cAMP
One of the studies58 prepared three 250 mL portions of
coffee for the participants to drink daily for four weeks,
and this coffee with caffeine has been shown to inhibit
PDE activity.58
On the other hand, in another experimental interven-
tion,60 two types of coffee were prepared: commercial
coffee with 618.1 mg/L and coffee with low caffeine con-
tent with 178.9 mg/L, both for one week. Both coffees
show an increase in PDE activity at the end of the inter-
vention, despite variations occurring over the same peri-
od,60 as well as the cAMP level.60 It is indicated that both
have 448 mg/L of CGA.
Coffee and adenosine receptors
Regarding adenosine, one of the studies58 prepared a
type of coffee, which he called SB (study mixture), by
mixing dark roasted coffee with portions of light roasted
coffee, and taking that coffee, over four weeks, there was
an increase in adenosine concentration.58
Coffee and platelets
One of the studies contemplated50 found that after a
period 1 of 10 days, with a cup of coffee, and a period
2 of 14 days, with the intake of 15 flat teaspoons of de-
caffeinated coffee, coffee has not been shown to interfere
with platelets.50 Two interventions49,59 indicate that the
acute consumption of a cup of coffee,49 or six cups of
coffee for two weeks,59 does not interfere with platelets
or platelet aggregation.
Three studies53,57,59 point to coffee as an agent that
can decrease/inhibit platelet aggregation, when it is in-
duced by collagen and arachidonic acid (acutely consum-
ing 200 mL of American coffee),57 collagen and 5 lg of
ADP (consuming 300 mL of chicory coffee for a
week),53 or when it is consumed together with a diet
rich in saturated fatty acids (SFA) for two weeks.59
However, two of the same studies referred to in the
previous paragraph53,59 show that coffee increases plate-
let aggregability, when it is induced by epinephrine and
10 lg of ADP (consuming 300 mL of chicory coffee for
a week),53 or when eaten together with a diet rich in poly-
unsaturated fatty acids (PUFA) for two weeks.59
Caffeine and adenosine receptors
Two interventions39,55 showed that consuming 250 mg
of caffeine, three times a day, for seven days, through the
oral route, there was an increase in the binding sites of
the adenosine receptor39 and their positive regulation.55
Caffeine and PAI-1
Only one of the analyzed authors56 looked at PAI-1,
noting that after taking 100 mg of caffeine three times
a day for a week, there was a decrease in it.56
Caffeine and platelets
One of the authors52 demonstrated that with the acute
intake of 100 mg caffeine pill there was stimulation of
platelet activation.52
One of the interventions40 consisted of ingesting
250 mg of caffeine in capsules for one week, checking
that there is no relationship between caffeine and platelet
aggregation.40 In another study,57 180 mg of caffeine was
used to create caffeine capsules, consumed acutely, and it
was found not to affect platelet aggregation.57 And with
the same conclusion, after an acute consumption inter-
vention54 in which 10 individuals ingested a 100 mg caf-
feine tablet, and only three individuals ingested a 200 mg























































caffeine tablet, it was found that this substance did not in-
terfere with platelets.54
On the other hand, in an intervention48 with ingestion
of 200 mg of caffeine orally, twice daily for two weeks,
there was a decrease in platelet aggregability.48 Like-
wise, in a previously mentioned study,56 with the inges-
tion of 100 mg of caffeine, three times a day, for a week,
there was a decrease in platelet aggregability.56
Caffeine and NECA
Only two studies39,55 reported NECA, verifying that
after ingesting 250 mg of caffeine orally, three times a
day, for seven days, there was an increase in platelet re-
sponse to NECA,39 and there were effects of the same on
platelet aggregation.55
CGA, PDE, and cAMP
As previously mentioned, in one of the studies,60 two
types of coffee were prepared: commercial coffee with
618.1 mg/L and coffee with low caffeine content with
178.9 mg/L, both consumed for one week. Both show in-
creased PDE activity,60 as well as the cAMP level60 and
it is indicated that both have 448 mg/L of CGA. How-
ever, conclusions about this specific component of coffee
are not drawn.
Diterpenes
This component of coffee is not evaluated in the arti-
cles contemplated for this systematic review, and results
are not obtained for them.
Discussion
This review aims at understanding the effect of coffee
or its components on platelets or their regulators. Three
studies show no effects of coffee consumption on
TXB2 and PGI2; likewise, four studies show no effects
on platelets, with coffee/caffeine consumption. On the
other hand, two studies show that after coffee consump-
tion there is inhibition of TXB2 and PDE, five studies
show that after coffee/caffeine consumption there is a
decrease/inhibition of platelet aggregation or its compo-
nents, and one of these reports that with caffeine the
PAI-1 decreases. Four articles report an increase in plate-
let regulators such as PDE, cAMP, and adenosine with
the consumption of coffee/caffeine. Two studies found
an increase in platelet aggregation after coffee consump-
tion, and three studies found that with caffeine consump-
tion there was platelet stimulation and effects on it with
the use of NECA. It should be noted that the heterogene-
ity of the studies, due to their different sample sizes,
doses applied, duration of treatments, evaluation of
results, and possible biases identified, may compromise
the veracity of the results found.
In general, 10 articles do not find a relationship be-
tween coffee or its components and platelets and their
regulators, 9 refer to associations that promote an in-
crease in aggregation, and 8 talk about associations that
promote a decrease in aggregation, which is why they
are considered inconclusive results. This may be due to
the different sample sizes, the presence of some types
of bias, the absence of isolation of the coffee components
in some studies, or the different doses of coffee/caffeine
administered, as will be explained later.
Coffee and prostanoids
Two studies indicate that there is no effect on throm-
boxanes42,51 after coffee consumption, whereas another
one indicates an inhibition of their formation.57 TXA2
has an aggregating action and spontaneously transforms
into TXB2. Intense platelet stimuli make the aggregation
irreversible and agents such as TXA2 induce the cellular
extrusion of substances accumulated in the platelet gran-
ules, called ‘‘release reaction.’’ Thus, TXA2 is co-
responsible, together with ADP, for the posterior growth
of the hemostatic plug.36 The observed inhibitory effect
can be explained if it is found that coffee is able to inhibit
platelets, because if this occurs, the factors necessary for
the production of TXA2 or its inactive form, TXB2, will
not be released from the platelets. Regarding the studies
that verify the lack of effect of coffee on thromboxanes,
they may present a bad classification bias and it should be
noted that the same occurred in the years 1985 and 1989,
being, therefore, older in relation to the study that ob-
serves the inhibition of the formation of this regulator.
Thus, there is a need for further studies in relation to
thromboxanes and coffee.
Only one of the studies analyzed looked at PGI2 and
was unable to verify the effect of coffee on it.61 PGI2
is released from vascular endothelial cells, producing va-
sodilation and inhibiting platelet aggregation, which al-
lows to counterbalance the actions of TXA2.64 The
conclusion obtained may be due to the type of interven-
tion performed, since there was no isolation of coffee, to
specifically study this drink in the action of PGI2, and
also due to loss of follow-up, reducing the sample size.
For more assertive conclusions, it would be useful to con-
duct a study focusing on coffee or its components and the
relationship with the regulator in question.
Coffee, PDE, and cAMP
One of the studies58 demonstrates that after the con-
sumption of coffee, there was an inhibition of PDE activ-
ity, which, by not performing its hydrolysis function, will
promote an increase in the concentration of cAMP,
which may be related to the inhibition of platelet aggre-
gation. PDEs are enzymes that are responsible for the
degradation of cyclic nucleotides in the cell, which
leads to an increase in intracellular concentrations of























































cAMP and cyclic 3’5’-guanosine monophosphate (cyclic
GMP or GMPc).65 Methylxanthines, such as caffeine,
prevent the conversion of cAMP to AMP, acting as
PDE inhibitors, increasing the inhibitory effects of aden-
osine on platelet aggregation.66 In this way, it could be
concluded that coffee influences the modulation of plate-
let aggregation, and, consequently, decreases platelet
count. However, this study contemplates coffee with caf-
feine, so the verified effect may be due to coffee as a
whole, or to one of its specific components.
The same is true for the other study60 that prepared
commercial coffee and coffee with a low caffeine con-
tent. Both verified an increase in the activity of PDE
and cAMP; however, throughout the intervention, the in-
hibition of activity and its subsequent increase were ver-
ified. The presence of the same amount of CGA in both
drinks with different caffeine content may explain the
variations in results throughout the experience, as well
as the loss of follow-up (loss of two people for personal
reasons).60 For further clarification on the real effect of
coffee on PDE and cAMP, as well as the consequent ef-
fect on platelet aggregation and counting, the isolation of
the different components of coffee and the observation of
their effect on platelets could be made.
Coffee and adenosine receptors
One of the contemplated studies58 notes that the coffee
mixture (SB) that was created in the experiment causes
an increase in adenosine concentrations. By doing so,
one may be stimulating an increase in the production
of cAMP by platelets, which will lead to inhibition of
platelet aggregation, that is, a decrease in platelet
count. Of the five subtypes of adenosine receptors,33,48
A2A was identified as being specifically expressed in
platelets.33,39 Both A2 adenosine receptors (A2A and
A2B) lead to stimulation of adenyl cyclase and conse-
quent elevation of cAMP.33 For the intervention carried
out, the different degrees of roasting used to create this
coffee mixture may be the reason for this conclusion,
as well as the different components of the coffee. As
such, further studies with this type of mixture should
be performed for more solid conclusions.
Coffee and platelets
Three studies refer to the lack of relationship between
coffee and platelets; however, two of them are old stud-
ies, 199059 and 1970,50 which may reveal a lack of updat-
ing of information relevant to the performance of the
experiment and bias of bad non-differential classifica-
tion. Among them, the most recent study dates back to
2018 and states the same as the previous ones; however,
it can also show bias of non-differential classification and
only studies the effect of drinking a cup of coffee,49 with
acute ingestion being not possible enough to detect some
kind of relationship. To this end, the study of chronic cof-
fee consumption would be conducive to obtaining more
credible information in establishing a relationship with
another component.
One of the included studies presents the inhibition of
platelet aggregation induced by arachidonic acid after
coffee consumption,57 and the literature reports that ara-
chidonic acid is the main substrate for the synthesis of ei-
cosanoids, inflammatory mediators of lipid origin,
exercising control in platelet aggregation.67 The con-
sumption of coffee on this type of inducer may cause in-
hibition of platelet aggregation. The same study indicates
a decrease in platelet aggregation after coffee consump-
tion, when it is induced by collagen.57 When adminis-
tered eicosapentaenoic acid (EPA), there is a reduction
in the response of platelets to collagen68; so, depending
on the type of diet, the response that platelets give to
their cascade regulators may be altered, which may
cause a decrease in platelet aggregability.
One of the studies analyzed shows the decreased effect
on platelets when coffee is consumed together with a diet
rich in SFA.59 The intake of diets rich in SFA is discour-
aged by both the increase in LDL cholesterol and the in-
creased risk of cardiovascular disease. The fact that they
predispose to thrombosis can lead to altered platelet
aggregation.69 Together with coffee, it may be possible
to observe a decrease in this effect on platelets; how-
ever, further studies should be performed for better
clarification.
ADP is relatively weak as a platelet stimulator,70 so
the inhibitory effect of coffee on platelet aggregation,53
when it is induced by 5 lg of ADP, can be explained
by the weak stimulation that this regulator has. On the
other hand, the same study finds that after coffee con-
sumption there is an increase in platelet aggregation,
when it is induced by 10 lg of ADP.53 Possibly the in-
crease in the concentration of this regulator associated
with the consumption of a stimulant, such as coffee,
may cause platelet aggregation.
In one of the studies contemplated, it appears that there
is an increase in platelet aggregability when it is induced
by epinephrine.53 Epinephrine, or adrenaline, is also one
of the regulators of platelet aggregation, known to be rel-
atively weak as a platelet stimulator.70 However, the ef-
fect obtained may be due to the consumption of coffee
during the test, becoming responsible for the increase
in aggregation.
Regarding regulators, one of the studies reported an in-
crease in platelet aggregation when coffee was consumed
together with a diet rich in PUFA.59 According to the lit-
erature, it is known that omega-3 fatty acids comprised
docosahexaenoic acid (DHA) and EPA of marine origin,
and a-linolenic acid (ALA) of plant origin. Among its
physiological and metabolic effects is the decrease in
platelet aggregation.67,71 This effect is contradicted in
this analysis, perhaps due to the joint consumption of
the diet rich in PUFA with coffee, or because it may























































present biases of poor non-differential classification and
social desirability. New studies analyzing the same vari-
ables should be carried out to better interpret the results.
Caffeine and adenosine receptors
Two of the included studies observed an increase in
the binding sites of the adenosine receptors,39 as well
as their positive supra-regulation.55 However, methyl-
xanthines, such as caffeine, are non-selective blockers
of the adenosine receptor,33 a purine released locally
that acts on different receptors. The result obtained
may be because both studies are old, that is, 1999 and
1991, respectively. In addition, both studies included a
small number of participants, 9 and 8 individuals, respec-
tively. For more consistent results, it would be necessary
to conduct studies with a larger number of participants.
Caffeine and PAI-1
One of the studies analyzed found a decrease in PAI-1
after taking caffeine.56 PAI-1 is a fast-acting fibrinolysis
inhibitor that acts on the regulation of plasmin activity,
through the formation of complexes that inactivate tissue
plasminogen activator (t-PA) and urokinase type plas-
minogen activator (u-PA), controlling plasminogen acti-
vation.72,73 Fibrinolysis is the process by which the fibrin
clot is destroyed and, since fibrin functions as a grid that
allows the maintenance of the platelet aggregation struc-
ture, in the event of an injury, it is necessary to control its
maintenance process.70 The fact that PAI-1 is decreased
with the consumption of caffeine can cause a decrease in
platelet aggregability, because the regulator will not be
as able to inhibit fibrinolysis.
Caffeine and platelets
One of the authors verified platelet activation after
consuming 100 mg of caffeine in a pill.52 Caffeine is
known to be a stimulating substance, which acts on the
body by blocking adenosine receptors, manifesting itself
by an increase in catecholamine secretion: adrenaline,
dopamine, and serotonin. With the consumption of caf-
feine, there is stimulation of the central nervous system,
increased heart rate, and dilation of blood vessels.74–77
Vasodilation causes redness, pain, and heat in the region;
so platelets, which are located on the periphery of blood
vessels, perform non-hemostatic functions, controlling
inflammation and wound healing.78 In the event of an in-
jury, platelets perform hemostatic functions, helping to
repair the vascular injury and preventing the occurrence
of bleeding by participating in the formation of the pri-
mary hemostatic plug. That is, in some way, caffeine
may be associated with platelet activation, one of the
stages of platelet metabolism.
Three studies40,54,57 did not find a relationship between
caffeine and platelet aggregability, which may present a
non-differential bias. These results may also be due to
the age of the articles dating from 198654 to 2000,40 as
well as the inclusion of a sample of only 13 individuals
in both. Another reason may be to perform the test in an
acute manner,57 an aspect that may not provide enough
time for the interaction of caffeine with platelets. More re-
cent trials that promote chronic caffeine consumption will
be needed to obtain more illuminating results.
On the other hand, two studies48,56 point to decreased
platelet aggregation when consuming caffeine, and in
both cases this substance is chronically ingested for
one56 and two48 weeks, respectively. One of these stud-
ies48 even uses a sample of 45 healthy individuals, con-
tributing to a large sample size, which can support the
veracity of the results obtained. In this way, different ex-
periments with a large sample size should be performed
to confirm or refute the observed results.
Caffeine and NECA
Both studies that focused on NECA indicated increased
platelet response to this regulator,39 and its effects on plate-
let aggregation.55 However, according to the literature,
NECA is an adenosine analogue that is 22,900 times
more potent than this as a vasodilator, which is responsible
for inhibiting human platelet aggregation induced by ADP,
adrenaline, 5-hydroxytryptamine (5 HT), and thrombin.79
One of the studies55 reports the effect of NECA on platelet
aggregation, but it does not clarify whether it is at the level
of inhibition of aggregation or stimulation. The increase in
platelet response seen in the other study39 may occur due to
caffeine stimulation over the NECA regulator. For better
clarification, further studies should focus on the relationship
between caffeine and NECA and the effect on platelets.
CGA, PDE, and cAMP
In the study60 that indicates an increase in PDE and
cAMP, the results observed may be due to loss of follow-
up (excluding two individuals), or to the similar CGA
content in both studied coffees. CGA is a group of phe-
nolic compounds formed from the esterification of quinic
acid with some derivatives of cinnamic acid (caffeic,
ferulic, and p-cumaric acid).80 However, the observed ef-
fect can also be associated with the degree of roasting or
the coffee species used in the experiment, since the CGA
content of a cup of coffee will depend mainly on these
factors (70–350 mg per 200 mL of drink).80 As such, fur-
ther studies are needed to isolate the CGA and verify its
effect on the PDE and, consequently, cAMP.
Diterpenes
This component of coffee is not evaluated by the arti-
cles included in this systematic review, and no results are
obtained for it.
Limitations: This review article may have some limita-
tions, such as the lack of data regarding the sample collec-
tion location, age group, or classification as to the type of























































study, considering the lack of information that some of the
included articles presented. One of the limitations of this
article is related to the high heterogeneity found, due to
various regimens, doses, duration, and other factors previ-
ously described at the different intervention periods. As
previously mentioned, most studies present possible bias
or confounding variables, so the results obtained may be
conditioned in this way. Likewise, there are variables
with a few studies focusing on them, such as at the level
of NECA and PAI-1, which may limit the conclusions to
be drawn about them. The incongruity of the results
found is also a limitation, because did not have a specific
conclusion on the relationship between coffee or its com-
ponents with platelets and their regulators.
Conclusion
Conclusively, there are results that do not corroborate
each other. However, there seems to be a relationship be-
tween coffee/caffeine consumption on platelets and their
regulators. The inhibition or promotion of platelet aggre-
gation may depend on the type of coffee component, the
beverage as a whole, the type of agonist used to induce
aggregation, joint consumption with other foods, or
other factors such as age and gender.
In short, consistent data are not obtained in the conclu-
sion drawn, so further studies should be carried out, indi-
vidualizing the components of the coffee during a
chronic consumption, allowing to verify the effect on the
platelets or their regulators. They should also consider a
significant sample size and consider the differences that
may result from the age and/or gender of the participants.
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na bebida relacionadas às doenças cardiovasculares1.
Rev Nutr. 2010;23:1063–1073.
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substance use, sleep, and academic achievement: Evidence
of harm due to caffeine. J Adolesc. 2011;34:665–673.
26. Weng X, Odouli R, Li DK. Maternal caffeine consump-
tion during pregnancy and the risk of miscarriage: A pro-
spective cohort study. Am J Obstet Gynecol. 2008;198:
279.e1–e279.e8.
27. Wachamo HL. Review on health benefit and risk of cof-
fee consumption. Med Aromat Plants. 2017;6:4.
28. Echeverri D, Pizano A, Montes FR, et al. Acute effect of
coffee consumption on arterial stiffness, evaluated using
an oscillometric method. Artery Res. 2017;17:16–32.
29. Sofi F, Conti AA, Gori AM, et al. Coffee consumption
and risk of coronary heart disease: A meta-analysis.
Nutr Metab Cardiovasc Dis. 2007;17:209–223.
30. Chang HH, Lo SJ. Full-spreading platelets induced by
the recombinant rhodostomin are via binding to integrins
and correlated with FAK phosphorylation. Toxicon.
1998;36:1087–1099.
31. Koupenova M, Clancy L, Corkrey H, et al. Circulating
platelets as mediators of immunity, inflammation and
thrombosis. Circ Res. 2018;122:337–351.
32. Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al.
Platelets: Versatile effector cells in hemostasis, inflam-
mation, and the immune continuum. Semin Immunopa-
thol. 2012;34:5–30.
33. Santhakumar AB, Fozzard N, Perkins AV, et al. The syner-
gistic effect of taurine and caffeine on platelet activity and
hemostatic function. Food Public Heal. 2013;3:147–153.
34. Middleton E, Rondina MT. Platelets in infectious dis-
ease. Hematology. 2016;2016:256–261.
35. McEwen BJ. The influence of diet and nutrients on plate-
let function. Semin Thromb Hemost. 2014;40:214–226.
36. Armaganijan D. Editorial Ativação Plaquetária nas For-
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Servi Saúde. 2015;4:2.
44. Moher D, Liberati A, Tetzlaff J AD. Preferred reporting
items for systematic reviews and meta-analyses: The
PRISMA Statement. PLoS Med. 2009;6:e1000097.
45. Selcuk AA. A Guide for Systematic Reviews: PRISMA.
Turkish Arch Otorhinolaryngol. 2019;57:57–58.
46. Aslam S, Emmanuel P. Formulating a researchable ques-
tion: A critical step for facilitating good clinical research.
Indian J Sex Transm Dis. 2010;31:47–50.
47. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA
2020 statement: an updated guideline for reporting sys-
tematic reviews. Syst Rev. 2021;10:89.
48. Varani K, Portaluppi F, Gessi S, et al. Dose and time ef-
fects of caffeine intake on human platelet adenosine
A(2A) receptors: Functional and biochemical aspects.
Circulation. 2000;102:285–289.
49. Krekels JPM, Verhezen PWM, Henskens YMC. Platelet
Aggregation in Healthy Participants is Not Affected by
Smoking, Drinking Coffee, Consuming a High-Fat
Meal, or Performing Physical Exercise. Clin Appl
Thromb Hemost. 2019:25:1076029618782445.
50. Naismith DJ, Akinyanju PA, Szanto S, et al. The effect in
volunteers of coffee and decaffeinated coffee on blood
glucose, insulin, plasma lipids and some factors involved
in blood clotting. Ann Nutr Metab. 1970;12:144–151.
51. Paoletti R, Corsini A, Tremoli E, et al. Effects of coffee
on plasma lipids, lipoproteins and apolipoproteins. Phar-
macol Res. 1989;21:27–38.
52. Ammaturo V, Perricone C, Canazio A, et al. Caffeine
stimulates in vivo platelet reactivity. Acta Med Scand.
1988;224:245–247.
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vs feminino: Factor relevante para as respostas farmaco-
lógicas e efeitos adversos de fármacos? Acta Farm Port.
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graxos poli-insaturados n-3 e n-6: Metabolismo em
mamı́feros e resposta imune. Rev Nutr. 2010;23:1075–
1086.
68. Castro A. Influencia Dos Ácidos Gordos Omega-3 Do
Peixe Na. Inst Super Ciências da Nutr da Univ do
Porto;1–41.
69. Chaveiro N. Bioacessibilidade de ácidos gordos em
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